// App-Quantinova.ai

OA08 : JAK inhibitors and the risk of malignancy: a meta-analysis across licenced disease indications

Researchers

Presenter

  • Christopher Stovin

Principal Investigators

  • Mark D Russell

  • Edward Alveyn

  • Olukemi Adeyemi

  • Vishit Patel

  • Maryam A Adas

  • Fabiola Atzeni

  • Kenrick K H Ng

  • Andrew I Rutherford

  • Sam Norton

  • Andrew P Cope

  • James B Galloway

Medical Centers

  • Rheumatology Unit, University of Verona, Verona, Italy

  • Department of Medical Oncology, University College London Hospital, London, United Kingdom

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Centre for Rheumatic Diseases, King’s College London, London, United Kingdom

Locations

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

  • Genetic Disorder

Disease

  • Inflammatory bowel disease

  • Axial spondyloarthritis

  • Psoriatic arthritis

  • Atopic Dermatitis

  • Spondyloarthritis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • Janus kinase

Drug/Treatment

  • ABT-494

  • Baricitinib

  • Tasocitinib

  • Peficitinib

  • Filgotinib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • II/III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved